50. 皮膚筋炎／多発性筋炎 Disease details / Clinical trials / Drug dev / DR info

0.9% W/V isotonic sodium chloride solution
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2017   Phase 3   EUCTR2016-002902-37-DE   Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Ukraine;United States
10% nifedipine cream
   Pontificia Universidad Catolica de Chile
      2016   Early Phase 1   NCT03027674   Chile
3 mpdn pulse + PDN + CSA
   Istituto Giannina Gaslini
      2006   Phase 3   NCT00323960   Italy
3 mpdn pulse + PDN + MTX
   Istituto Giannina Gaslini
      2006   Phase 3   NCT00323960   Italy
35MG
   Belfast Health and Social Care Trust, Musgrave Park Hospital
      2006   Phase 4   EUCTR2005-003129-23-GB   United Kingdom
44/154/85-C
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-CZ   Czech Republic;Sweden
44/196/81-C
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-CZ   Czech Republic;Sweden
5% sildenafil cream
   Pontificia Universidad Catolica de Chile
      2016   Early Phase 1   NCT03027674   Chile
56/104/75-C
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-CZ   Czech Republic;Sweden
5MG
   Belfast Health and Social Care Trust, Musgrave Park Hospital
      2006   Phase 4   EUCTR2005-003129-23-GB   United Kingdom
   Department of rheumatology, China-Japan Friendship hospital
      2013   -   ChiCTR-TRC-13003178   China
   Furuta Shunsuke
      2024   Phase 2   JPRN-jRCT2031240191   -
Abatacept
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2018   Phase 3   EUCTR2016-002269-77-IT   Australia;Brazil;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Mexico;Sweden;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-002269-77-SE   Australia;Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Sweden;United States
      2017   Phase 3   EUCTR2016-002269-77-FR   Australia;Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Sweden;United States
      2017   Phase 3   EUCTR2016-002269-77-DE   Australia;Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Sweden;United States
      2017   Phase 3   EUCTR2016-002269-77-CZ   Australia;Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Sweden;United States
   George Washington University
      2015   Phase 4   NCT02594735   United States
   Karolinska University Hospital
      2012   -   EUCTR2009-015957-20-GB   Sweden;United Kingdom
      2011   Phase 2   EUCTR2009-015957-20-CZ   Czech Republic;Sweden;United Kingdom
      2010   -   EUCTR2009-015957-20-SE   Sweden;United Kingdom
   Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
      2020   Phase 0   ChiCTR2000036282   China
   The First Affiliated Hospital with Nanjing Medical University
      2021   Early Phase 1   NCT04946669   China
Abatacept active treatment
   Karolinska Institutet
      2011   Phase 2   NCT01315938   Czech Republic;Czechia;Sweden
Abatacept delayed-onset treatment
   Karolinska Institutet
      2011   Phase 2   NCT01315938   Czech Republic;Czechia;Sweden
Abatacept subcutaneous
   Bristol-Myers Squibb
      2017   Phase 3   NCT02971683   Australia;Brazil;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Sweden;United States
   Bristol-Myers Squibb K.K.
      2017   Phase 3   JPRN-jRCT2080223614   Asia except Japan;Europe;Japan;North America;Oceania;South America
Acthar
   Phoenix Neurological Associates, LTD
      2013   -   NCT01637064   United States
AD26.COV2.S
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
Adrenocorticotropic hormone GEL
   Rohit Aggarwal, MD
      2013   Phase 2   NCT01906372   United States
Alendronate
   UMC Utrecht
      2000   Phase 3   NCT00138983   Netherlands
Alfacalcidol
   UMC Utrecht
      2000   Phase 3   NCT00138983   Netherlands
Alfacalcidol 2 micrograms/ML
   Belfast Health and Social Care Trust, Musgrave Park Hospital
      2006   Phase 4   EUCTR2005-003129-23-GB   United Kingdom
ALXN1210
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-IT   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States
   Alexion Pharmaceuticals, Inc.
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-FR   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-ES   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Peru;Poland;Serbia;Spain;Sweden;Taiwan;Türkiye;United Kingdom;United States
Anakinra
   Karolinska Institutet
      2003   Phase 2/Phase 3   NCT01165008   Sweden
Anifrolumab
   Ageishi Yuji
      2024   Phase 3   JPRN-jRCT2031240240   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Mexico;Netherlands;Poland;South Korea;Spain;Sweden;Taiwan;United Kingdom;United States of America;Vietnam
   AstraZeneca
      2024   Phase 3   NCT06455449   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Spain;Sweden;Taiwan;United Kingdom;United States;Vietnam
ANTI-CD19 CAR T cell therapy
   University of Erlangen-Nürnberg Medical School
      2023   Phase 1/Phase 2   NCT06347718   Germany
ANTI-CD19 UCAR-T cells
   Chongqing Precision Biotech Co., Ltd
      2024   Phase 1   NCT06686524   China
ANTI-pandemic H1n1 influenza vaccine
   University of Sao Paulo
      2010   Phase 4   NCT01151644   Brazil
Apremilast
   Okiyama Naoko
      2020   Phase 1-2   JPRN-jRCTs031200005   -
   Stanford University
      2010   -   NCT01140503   United States
Apremilast 30MG
   Tulane University
      2018   Phase 2   NCT03529955   United States
BAF312
   Novartis Pharma Services AG
      2009   -   EUCTR2008-006311-21-SE   Czech Republic;Hungary;Sweden;United Kingdom
      2009   -   EUCTR2008-006311-21-HU   Czech Republic;Hungary;Sweden;United Kingdom
   Novartis Pharmaceuticals
      2013   Phase 2   NCT02029274   Belgium;Canada;China;Czech Republic;Czechia;Hungary;Japan;Netherlands;Poland;Switzerland;Taiwan;United States
      2013   Phase 2   NCT01801917   Belgium;Canada;Czech Republic;Czechia;Hungary;Netherlands;Poland;Switzerland;Taiwan;United States
      2010   Phase 2   NCT01148810   Czech Republic;Czechia;Hungary;Poland;Sweden;United Kingdom;United States
BAF312 0,5 MG tablet
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2012-002859-42-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Taiwan;United States
BAF312 0.25 MG
   Novartis Pharma Services AG
      2013   -   EUCTR2013-001799-39-HU   Belgium;Canada;China;Czech Republic;Germany;Hungary;Japan;Netherlands;Poland;Switzerland;Taiwan;United States
      2013   -   EUCTR2013-001799-39-CZ   Canada;Czech Republic;Germany;Hungary;Japan;Poland;United States
BAF312 0.25 MG tablet
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2012-002859-42-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Taiwan;United States
      2013   Phase 2   EUCTR2012-002859-42-HU   Belgium;Canada;Czech Republic;Hungary;Poland;United States
      2013   Phase 2   EUCTR2012-002859-42-CZ   Belgium;Canada;Czech Republic;Hungary;Poland;United States
      2009   Phase 2   EUCTR2008-006311-21-GB   Czech Republic;Hungary;Sweden;United Kingdom
BAF312 0.25MG tablet
   Novartis Pharma Services AG
      2009   -   EUCTR2008-006311-21-CZ   Czech Republic;Hungary;Sweden;United Kingdom
BAF312 0.5 MG
   Novartis Pharma Services AG
      2013   -   EUCTR2013-001799-39-CZ   Canada;Czech Republic;Germany;Hungary;Japan;Poland;United States
BAF312 0.50 MG
   Novartis Pharma Services AG
      2013   -   EUCTR2013-001799-39-HU   Belgium;Canada;China;Czech Republic;Germany;Hungary;Japan;Netherlands;Poland;Switzerland;Taiwan;United States
BAF312 1 MG
   Novartis Pharma Services AG
      2013   -   EUCTR2013-001799-39-CZ   Canada;Czech Republic;Germany;Hungary;Japan;Poland;United States
BAF312 1 MG tablet
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2012-002859-42-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Taiwan;United States
      2013   Phase 2   EUCTR2012-002859-42-HU   Belgium;Canada;Czech Republic;Hungary;Poland;United States
      2013   Phase 2   EUCTR2012-002859-42-CZ   Belgium;Canada;Czech Republic;Hungary;Poland;United States
      2009   Phase 2   EUCTR2008-006311-21-GB   Czech Republic;Hungary;Sweden;United Kingdom
BAF312 1MG
   Novartis Pharma Services AG
      2013   -   EUCTR2013-001799-39-HU   Belgium;Canada;China;Czech Republic;Germany;Hungary;Japan;Netherlands;Poland;Switzerland;Taiwan;United States
BAF312 1MG tablet
   Novartis Pharma Services AG
      2009   -   EUCTR2008-006311-21-CZ   Czech Republic;Hungary;Sweden;United Kingdom
BAF312 2 MG
   Novartis Pharma Services AG
      2013   -   EUCTR2013-001799-39-CZ   Canada;Czech Republic;Germany;Hungary;Japan;Poland;United States
BAF312 2 MG tablet
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2012-002859-42-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Taiwan;United States
BAF312 2MG
   Novartis Pharma Services AG
      2013   -   EUCTR2013-001799-39-HU   Belgium;Canada;China;Czech Republic;Germany;Hungary;Japan;Netherlands;Poland;Switzerland;Taiwan;United States
BAF312 4MG tablet
   Novartis Pharma Services AG
      2009   Phase 2   EUCTR2008-006311-21-GB   Czech Republic;Hungary;Sweden;United Kingdom
      2009   -   EUCTR2008-006311-21-CZ   Czech Republic;Hungary;Sweden;United Kingdom
BAF312 5 MG tablet
   Novartis Pharma Services AG
      2009   Phase 2   EUCTR2008-006311-21-GB   Czech Republic;Hungary;Sweden;United Kingdom
      2009   -   EUCTR2008-006311-21-CZ   Czech Republic;Hungary;Sweden;United Kingdom
BAF312 hemifumarate
   Novartis Pharma Services AG
      2014   -   EUCTR2013-001799-39-PL   Canada;Czech Republic;Germany;Hungary;Japan;Poland;United States
      2014   Phase 2   EUCTR2013-001799-39-BE   Belgium;Canada;Czech Republic;Germany;Hungary;Japan;Poland;Taiwan;United States
      2014   Phase 2   EUCTR2012-002859-42-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Taiwan;United States
      2013   -   EUCTR2013-001799-39-HU   Belgium;Canada;China;Czech Republic;Germany;Hungary;Japan;Netherlands;Poland;Switzerland;Taiwan;United States
      2013   -   EUCTR2013-001799-39-CZ   Canada;Czech Republic;Germany;Hungary;Japan;Poland;United States
      2013   Phase 2   EUCTR2012-002859-42-PL   Belgium;Canada;Czech Republic;Hungary;Poland;Switzerland;Taiwan;United States
      2013   Phase 2   EUCTR2012-002859-42-HU   Belgium;Canada;Czech Republic;Hungary;Poland;United States
      2013   Phase 2   EUCTR2012-002859-42-CZ   Belgium;Canada;Czech Republic;Hungary;Poland;United States
BAF312X
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2012-002859-42-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Taiwan;United States
      2013   Phase 2   EUCTR2012-002859-42-PL   Belgium;Canada;Czech Republic;Hungary;Poland;Switzerland;Taiwan;United States
      2013   Phase 2   EUCTR2012-002859-42-HU   Belgium;Canada;Czech Republic;Hungary;Poland;United States
      2013   Phase 2   EUCTR2012-002859-42-CZ   Belgium;Canada;Czech Republic;Hungary;Poland;United States
Baricitinib
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT05524311   France
      2022   Phase 3   NCT04972760   France
   Assistance Publique des Hôpitaux de Paris
      2022   Phase 2   EUCTR2022-000506-10-FR   France
   Assistance Publique-Hopitaux de Paris
      2021   Phase 3   EUCTR2020-004987-24-FR   France
   Eli Lilly and Company
      2012   -   NCT01724580   United Kingdom;United States
      -   Phase 2   EUCTR2015-003424-31-GB   France;United Kingdom;United States
   Fujio Keishi
      2023   Phase 2   JPRN-jRCTs031220641   -
   University of Washington
      2022   Phase 2   NCT05361109   United States
Basiliximab
   RenJi Hospital
      2017   Phase 2   NCT03192657   China
Begelomab
   ADIENNE SA
      2021   Phase 2   EUCTR2021-000898-83-IT   Italy
Biospecimen collection
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States
BNT162b2, bivalent
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
Brepocitinib
   Priovant Therapeutics, Inc.
      2024   Phase 2   NCT06433999   United States
      2022   Phase 3   NCT05437263   Argentina;Belgium;Bulgaria;Canada;Chile;Czechia;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
CABA-201 following preconditioning with fludarabine and cyclophosphamide
   Cabaletta Bio
      2023   Phase 1/Phase 2   NCT06154252   United Kingdom;United States
Calcineurin inhibitors
   RenJi Hospital
      2017   Phase 2   NCT03192657   China
CAR T cell
   Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      2024   Phase 1/Phase 2   NCT06685042   Italy
CD19 targeted CAR-T cells
   Chongqing Precision Biotech Co., Ltd
      2023   Phase 1   NCT06056921   China
CD19-targetd CAR-T
   Chongqing Precision Biotech Co., Ltd
      2024   Phase 1   NCT06569472   China
CD7 CAR T-cells
   Zhejiang University
      2022   Early Phase 1   NCT05239702   China
Cervarix suspensie voor injectie
   University Medical Center Utrecht
      2009   -   EUCTR2008-008169-36-NL   Netherlands
Childhood health assessment questionnaire
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT05524311   France
CHQ
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT05524311   France
Ciclosporin
   ISTITUTO GIANNINA GASLINI
      2006   -   EUCTR2005-003956-37-IT   Belgium;Italy;Netherlands;Sweden;United Kingdom
   Istituto Giannina Gaslini
      2006   -   EUCTR2005-003956-37-NL   Belgium;Italy;Netherlands;Sweden;United Kingdom
Colchicine
   Lanzhou University Second Hospital
      2023   Phase 4   ChiCTR2200067219   China
Creapure
   The Hospital for Sick Children
      2015   -   NCT02267005   Canada
Creatine
   University of Sao Paulo
      2011   -   NCT01217320   Brazil
CYA
   Department of Neurology and Rheumatology, Shinshu University School of Medicine
      2009   -   JPRN-UMIN000001866   Japan
Cyclophosphamide
   Department of Rheumatology and Immunology, Tianjin Medical University General Hospital
      2020   Phase 4   ChiCTR1900028143   China
   First Affiliated Hospital of Nanjing Medical University
      2022   Phase 4   ChiCTR2200059159   China
   Furuta Shunsuke
      2024   Phase 2   JPRN-jRCT2031240191   -
   Kyushu University
      2010   Phase 2   JPRN-UMIN000031931   Japan
   Zhongshan Hospital of Fudan University
      2020   -   ChiCTR2000036709   China
Cyclophosphamide injection 1G
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom
Cyclosporin
   Zhongshan Hospital of Fudan University
      2020   -   ChiCTR2000036709   China
Cyclosporine
   Istituto Giannina Gaslini
      2006   Phase 3   EUCTR2005-003956-37-DK   Belgium;Denmark;Italy;Netherlands;Sweden;United Kingdom
   Second Division, Department of Internal medicine, Hamamatsu University School of Medicine
      2014   -   JPRN-UMIN000015469   Japan
Cyclosporine A
   Istituto Giannina Gaslini
      2008   -   EUCTR2005-003956-37-GB   Belgium;Italy;Netherlands;Sweden;United Kingdom
      2007   -   EUCTR2005-003956-37-SE   Belgium;Italy;Netherlands;Sweden;United Kingdom
   University Hospital Gent
      2006   Phase 3   EUCTR2005-003956-37-BE   Belgium;Denmark;Italy;Netherlands;Sweden;United Kingdom
Daxdilimab
   Amgen
      2023   Phase 2   NCT05669014   Argentina;Australia;Brazil;Czechia;Germany;Italy;Mexico;Spain;United Kingdom;United States
Dazukibart
   Pfizer
      2025   Phase 3   NCT06698796   Bulgaria;China;United States
Delgocitinib
   Watanabe Tomoya
      2024   Phase 2   JPRN-jRCTs031230077   -
Denosumab
   Indiana University
      2019   Phase 1/Phase 2   NCT02418273   United States
Dosage OF cytokines
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT05524311   France
DR-0201
   Dren Bio
      2025   Phase 1   NCT06647069   Australia;Bosnia and Herzegovina;Bulgaria;New Zealand;Poland;Serbia;South Africa
DUAL-therapy
   The First Affiliated Hospital with Nanjing Medical University
      2022   Phase 4   NCT05375435   China
EFG PH20 SC
   argenx
      2023   Phase 3   NCT05979441   Argentina;Austria;Belgium;Bulgaria;Cyprus;Czechia;Denmark;France;Georgia;Germany;Greece;Italy;Korea, Republic of;Lithuania;Netherlands;Peru;Poland;Portugal;Serbia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States
      2022   Phase 2/Phase 3   NCT05523167   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Cyprus;Czechia;Denmark;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
Emea/H/C/000701
   Karolinska University Hospital
      2012   -   EUCTR2009-015957-20-GB   Sweden;United Kingdom
Empasiprubart IV
   argenx
      2024   Phase 2   NCT06284954   Georgia;Greece;Italy;Moldova, Republic of;Poland;Spain;United States
Etanercept
   Brigham and Women's Hospital
      2006   Phase 1   NCT00112385   United States
   Children's Hospital Medical Center, Cincinnati
      2002   Phase 2/Phase 3   NCT00035958   United States
Fractionated carbon dioxide (FCO2) laser
   Alison Ehrlich
      2012   Phase 2   NCT01572844   United States
Froniglutide
   Immunoforge Co. Ltd.
      2023   Phase 2   NCT05833711   Korea, Republic of
Gamma globulin
   National Institute of Neurological Disorders and Stroke (NINDS)
      1990   Phase 2   NCT00001261   United States
GB-0998
   Japan Blood Products Organization
      2006   Phase 3   NCT00335985   Japan
      2006   Phase 3   JPRN-jRCT2080220256   Japan
Gevokizumab
   Institut de Recherches Internationales Servier (IRIS)
      2014   -   EUCTR2012-005772-34-GR   Australia;Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Poland;South Africa;Spain;Sweden;United Kingdom
      2014   -   EUCTR2012-005772-34-BE   Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Poland;South Africa;Spain;Sweden;United Kingdom
      2013   -   EUCTR2012-005772-34-SE   Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Poland;South Africa;Spain;Sweden;United Kingdom
      2013   Phase 2   EUCTR2012-005772-34-IT   Argentina;Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
      2013   -   EUCTR2012-005772-34-HU   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;Sweden;United Kingdom
      2013   -   EUCTR2012-005772-34-DE   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;Sweden;United Kingdom
      2013   Phase 2   EUCTR2012-005772-34-CZ   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
   Laboratorios Servier S.L
      2013   -   EUCTR2012-005772-34-ES   Argentina;Belgium;Brazil;Czech Republic;Denmark;France;Germany;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
   Servier Research and Development Ltd.
      2014   Phase 2   EUCTR2012-005772-34-GB   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
GLPG3667
   Galapagos NV
      2023   Phase 2   NCT05695950   Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;Czechia;France;Germany;Italy;Mexico;Poland;Romania;Spain;United Kingdom;United States
Glucose tablet
   The Hospital for Sick Children
      2015   -   NCT02267005   Canada
Grapefruit
   Department of Rheumatology and Clinical Immunology, Kyoto University Hospital
      2014   -   JPRN-UMIN000013546   Japan
H.P. acthar GEL
   The Cleveland Clinic
      2015   Phase 4   NCT02245841   United States
H5g1.1-MAB
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2000   Phase 2   NCT00005571   United States
Hbvaxpro
   Radboud University Nijmegen Medical Centre
      2008   -   EUCTR2008-001282-28-NL   Netherlands
Herpes zoster vaccine
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
Hizentra
   CSL BEHRING GMBH
      2019   Phase 3   EUCTR2018-003171-35-IT   Argentina;Australia;Canada;European Union;France;Germany;Italy;Japan;Mexico;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States
   CSL Behring K.K.
      2019   Phase 3   JPRN-jRCT2080224869   Europe;Japan;North America;Oceania;South America
   CSL Behring LLC
      2023   Phase 3   EUCTR2018-003171-35-HU   Argentina;Australia;Belgium;European Union;France;Germany;Hungary;Italy;Japan;Mexico;Russian Federation;Switzerland;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003171-35-DE   Argentina;Australia;Belgium;European Union;France;Germany;Hungary;Italy;Japan;Mexico;Russian Federation;Switzerland;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003171-35-FR   Argentina;Australia;Belgium;Canada;European Union;France;Germany;Hungary;Italy;Japan;Mexico;Russian Federation;Switzerland;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003171-35-ES   Argentina;Australia;Canada;European Union;France;Germany;Japan;Mexico;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003171-35-BE   Argentina;Australia;Belgium;European Union;France;Germany;Hungary;Italy;Japan;Mexico;Russian Federation;Switzerland;Ukraine;United Kingdom;United States
   Thomas Jefferson University
      2014   Early Phase 1   NCT02271165   United States
Human albumin
   CSL Behring K.K.
      2019   Phase 3   JPRN-jRCT2080224869   Europe;Japan;North America;Oceania;South America
Human immunoglobulin G
   CSL BEHRING GMBH
      2019   Phase 3   EUCTR2018-003171-35-IT   Argentina;Australia;Canada;European Union;France;Germany;Italy;Japan;Mexico;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States
   CSL Behring
      2019   Phase 3   NCT04044690   Argentina;Australia;Belgium;Czechia;France;Germany;Hungary;Italy;Japan;Mexico;Netherlands;Poland;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States
   CSL Behring K.K.
      2019   Phase 3   JPRN-jRCT2080224869   Europe;Japan;North America;Oceania;South America
   CSL Behring LLC
      2023   Phase 3   EUCTR2018-003171-35-HU   Argentina;Australia;Belgium;European Union;France;Germany;Hungary;Italy;Japan;Mexico;Russian Federation;Switzerland;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003171-35-DE   Argentina;Australia;Belgium;European Union;France;Germany;Hungary;Italy;Japan;Mexico;Russian Federation;Switzerland;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003171-35-FR   Argentina;Australia;Belgium;Canada;European Union;France;Germany;Hungary;Italy;Japan;Mexico;Russian Federation;Switzerland;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003171-35-ES   Argentina;Australia;Canada;European Union;France;Germany;Japan;Mexico;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003171-35-BE   Argentina;Australia;Belgium;European Union;France;Germany;Hungary;Italy;Japan;Mexico;Russian Federation;Switzerland;Ukraine;United Kingdom;United States
Human normal immunoglobulin
   Japan Blood Products Organization
      2006   Phase 3   JPRN-jRCT2080220256   Japan
   Octapharma Pharmazeutika Produktionsges.m.b.H
      2018   Phase 3   EUCTR2017-002710-31-RO   Canada;Czech Republic;Germany;Hungary;Romania;Russian Federation;United States
      2018   Phase 3   EUCTR2017-002710-31-HU   Canada;Czech Republic;Germany;Hungary;Russian Federation;United States
      2018   Phase 3   EUCTR2017-002710-31-DE   Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;United States
      2018   Phase 3   EUCTR2017-002710-31-CZ   Canada;Czech Republic;Germany;Hungary;Russian Federation;United States
   Orfagen
      2006   -   EUCTR2005-002463-88-DE   Austria;Czech Republic;Germany;Hungary;Italy
      2006   -   EUCTR2005-002463-88-AT   Austria;Czech Republic;Germany;Hungary;Italy
Humanised IGG1K monoclonal antibody against interferon beta
   PFIZER INC
      2021   Phase 2   EUCTR2020-004228-41-IT   Germany;Hungary;Italy;Poland;Spain;United States
   Pfizer Inc.
      2022   Phase 2   EUCTR2021-004787-10-PL   Australia;Germany;Hungary;Italy;Poland;Spain;United States
      2022   Phase 2   EUCTR2021-004787-10-HU   Australia;Germany;Hungary;Italy;Poland;Spain;United States
      2022   Phase 2   EUCTR2021-004787-10-ES   Australia;Germany;Hungary;Italy;Poland;Spain;United States
      2022   Phase 2   EUCTR2021-004787-10-DE   Australia;Germany;Hungary;Italy;Poland;Spain;United States
      2021   Phase 2   EUCTR2020-004228-41-PL   Germany;Hungary;Italy;Poland;Spain;United States
      2021   Phase 2   EUCTR2020-004228-41-HU   Germany;Hungary;Italy;Poland;Spain;United States
      2021   Phase 2   EUCTR2020-004228-41-ES   Germany;Hungary;Italy;Poland;Spain;United States
      2021   Phase 2   EUCTR2020-004228-41-DE   Germany;Hungary;Italy;Poland;Spain;United States
IFN-K
   Neovacs SA
      2016   Phase 2   EUCTR2016-000137-52-DE   France;Germany;Italy;Switzerland;United Kingdom
IFN-kinoid
   Neovacs
      2017   Phase 2   NCT02980198   France;Germany;Italy;Switzerland;United Kingdom
IFN-kinoid drug substance
   Neovacs SA
      2016   Phase 2   EUCTR2016-000137-52-DE   France;Germany;Italy;Switzerland;United Kingdom
IFNA-kinoid
   Neovacs SA
      2016   Phase 2   EUCTR2016-000137-52-DE   France;Germany;Italy;Switzerland;United Kingdom
IG vena
   Orfagen
      2010   -   EUCTR2005-002463-88-HU   Austria;Czech Republic;Germany;Hungary;Italy
      2009   -   EUCTR2005-002463-88-CZ   Austria;Czech Republic;Germany;Hungary;Italy
      2006   -   EUCTR2005-002463-88-DE   Austria;Czech Republic;Germany;Hungary;Italy
      2006   -   EUCTR2005-002463-88-AT   Austria;Czech Republic;Germany;Hungary;Italy
Igpro20
   CSL BEHRING GMBH
      2019   Phase 3   EUCTR2018-003171-35-IT   Argentina;Australia;Canada;European Union;France;Germany;Italy;Japan;Mexico;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States
   CSL Behring K.K.
      2019   Phase 3   JPRN-jRCT2080224869   Europe;Japan;North America;Oceania;South America
   CSL Behring LLC
      2023   Phase 3   EUCTR2018-003171-35-HU   Argentina;Australia;Belgium;European Union;France;Germany;Hungary;Italy;Japan;Mexico;Russian Federation;Switzerland;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003171-35-DE   Argentina;Australia;Belgium;European Union;France;Germany;Hungary;Italy;Japan;Mexico;Russian Federation;Switzerland;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003171-35-FR   Argentina;Australia;Belgium;Canada;European Union;France;Germany;Hungary;Italy;Japan;Mexico;Russian Federation;Switzerland;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003171-35-ES   Argentina;Australia;Canada;European Union;France;Germany;Japan;Mexico;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003171-35-BE   Argentina;Australia;Belgium;European Union;France;Germany;Hungary;Italy;Japan;Mexico;Russian Federation;Switzerland;Ukraine;United Kingdom;United States
Igvena*FL 200ML 10G+SET
   ORFAGEN
      2006   -   EUCTR2005-002463-88-IT   Austria;Czech Republic;Germany;Hungary;Italy
Immunoglobulin G
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2018   Phase 3   EUCTR2016-002902-37-NL   Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Ukraine;United States
      2017   Phase 3   EUCTR2016-002902-37-HU   Canada;Czech Republic;France;Germany;Hungary;Poland;Russian Federation;United States
      2017   Phase 3   EUCTR2016-002902-37-DE   Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Ukraine;United States
      2016   Phase 3   EUCTR2016-002902-37-CZ   Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Ukraine;United States
Immunosuppressive agents
   Karolinska University Hospital
      2010   -   NCT01813617   Sweden
IMO-8400
   Idera Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2015-003277-15-SE   Czech Republic;Hungary;Sweden;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003277-15-HU   Czech Republic;Hungary;Sweden;United Kingdom;United States
      2016   Phase 2   EUCTR2015-003277-15-GB   Czech Republic;Hungary;Sweden;United Kingdom;United States
IMO-8400 dose group 1
   Idera Pharmaceuticals, Inc.
      2015   Phase 2   NCT02612857   Hungary;United Kingdom;United States
IMO-8400 dose group 2
   Idera Pharmaceuticals, Inc.
      2015   Phase 2   NCT02612857   Hungary;United Kingdom;United States
Infliximab
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 2   NCT00033891   United States
Influvac
   Radboud University Nijmegen Medical Centre
      2008   -   EUCTR2008-001282-28-NL   Netherlands
Interferon beta
   Kawai Norisuke
      2023   Phase 3   JPRN-jRCT2031230382   Japan;United States
Interleukin-2
   Peking University People's Hospital
      2022   Phase 3   NCT05495321   China
ISA 51
   Neovacs
      2017   Phase 2   NCT02980198   France;Germany;Italy;Switzerland;United Kingdom
Isotone kochsalz-Lösung 0,9 % braun infusionslösung
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2017   Phase 3   EUCTR2016-002902-37-DE   Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Ukraine;United States
Itolizumab
   Biotech Pharmaceutical Co., Ltd.
      2023   Phase 1   NCT05986162   -
JAK inhibitor
   First Affiliated Hospital Xi'an Jiaotong University
      2020   Phase 4   NCT04966884   China
JBT-101
   CORBUS PHARMACEUTICALS, INC
      2019   Phase 3   EUCTR2018-003273-10-IT   Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;United States
   Corbus Pharmaceuticals Inc.
      2015   Phase 2   NCT02466243   United States
   Corbus Pharmaceuticals, Inc.
      2020   Phase 2;Phase 3   EUCTR2020-001762-11-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2020   Phase 2;Phase 3   EUCTR2020-001762-11-GB   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-SE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-HU   Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Serbia;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-GB   Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Serbia;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-ES   Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Serbia;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-DE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-CZ   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-BG   Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2020-001762-11-SE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2020-001762-11-DE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2020-001762-11-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
KYV-101
   Stanford University
      2024   Phase 1   NCT06298019   United States
KZR-616
   Kezar Life Sciences, Inc.
      2020   Phase 2   NCT04628936   United States
      2020   Phase 2   NCT04033926   Czechia;Germany;Poland;United States
KZR-616 maleate
   Kezar Life Sciences, Inc.
      2022   Phase 2   EUCTR2020-004382-39-CZ   Czech Republic;Czechia
      2021   Phase 2   EUCTR2019-002605-22-DE   Czech Republic;Czechia;Germany;Poland;United States
      2020   Phase 2   EUCTR2019-002605-22-CZ   Czech Republic;Czechia;Germany;Hungary;Poland;United States
L0133
   Orfagen
      2010   -   EUCTR2005-002463-88-HU   Austria;Czech Republic;Germany;Hungary;Italy
      2009   -   EUCTR2005-002463-88-CZ   Austria;Czech Republic;Germany;Hungary;Italy
      2006   -   EUCTR2005-002463-88-DE   Austria;Czech Republic;Germany;Hungary;Italy
      2006   -   EUCTR2005-002463-88-AT   Austria;Czech Republic;Germany;Hungary;Italy
Lenabasum
   CORBUS PHARMACEUTICALS, INC
      2019   Phase 3   EUCTR2018-003273-10-IT   Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;United States
   Corbus Pharmaceuticals, Inc.
      2020   Phase 2;Phase 3   EUCTR2020-001762-11-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2020   Phase 2;Phase 3   EUCTR2020-001762-11-GB   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-SE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-HU   Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Serbia;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-GB   Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Serbia;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-ES   Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Serbia;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-DE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-CZ   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-BG   Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2020-001762-11-SE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2020-001762-11-DE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2020-001762-11-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
   Corbus Pharmaceuticals, Inc. / CMIC Co., Ltd.
      2019   Phase 3   JPRN-jRCT2080224821   Asia except Japan;Europe;Japan;North America
LY3009104
   Eli Lilly and Company
      -   Phase 2   EUCTR2015-003424-31-GB   France;United Kingdom;United States
M5049 high dose
   EMD Serono Research & Development Institute, Inc.
      2023   Phase 2   NCT05650567   Czechia;Germany;Greece;Italy;Poland;Spain;United Kingdom;United States
Mabthera
   Karolinska University Hospital
      2008   Phase 2   EUCTR2006-000078-65-GB   Czech Republic;Sweden;United Kingdom
      2007   -   EUCTR2006-000078-65-SE   Czech Republic;Sweden;United Kingdom
      2007   Phase 2   EUCTR2006-000078-65-CZ   Czech Republic;Sweden;United Kingdom
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom
MEDI-545
   MedImmune LLC
      2008   Phase 1   NCT00533091   United States
MEDI7734
   Amgen
      2016   Phase 1   NCT02780674   United States
Mesenchymal stem cells
   National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
      2025   Phase 1/Phase 2   NCT06888973   Pakistan
Methimazole
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      1995   Phase 2   NCT00001421   United States
Methotrexat lachema 2,5MG
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-CZ   Czech Republic;Sweden
Methotrexat lachema 5 INJ. SOL
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-CZ   Czech Republic;Sweden
Methotrexate
   Children's Hospital Medical Center, Cincinnati
      2002   Phase 2/Phase 3   NCT00035958   United States
   ISTITUTO GIANNINA GASLINI
      2006   -   EUCTR2005-003956-37-IT   Belgium;Italy;Netherlands;Sweden;United Kingdom
   Institute of Rheumatology, Prague
      2008   Phase 3   NCT00651040   Czech Republic
   Istituto Giannina Gaslini
      2008   -   EUCTR2005-003956-37-GB   Belgium;Italy;Netherlands;Sweden;United Kingdom
      2007   -   EUCTR2005-003956-37-SE   Belgium;Italy;Netherlands;Sweden;United Kingdom
      2006   -   EUCTR2005-003956-37-NL   Belgium;Italy;Netherlands;Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-003956-37-DK   Belgium;Denmark;Italy;Netherlands;Sweden;United Kingdom
   Shintaro Hirata
      2023   Phase 2   JPRN-jRCT1061230085   -
   University Hospital Gent
      2006   Phase 3   EUCTR2005-003956-37-BE   Belgium;Denmark;Italy;Netherlands;Sweden;United Kingdom
Methotrexate lachema 5INJ. SOL
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-CZ   Czech Republic;Sweden
Methotrexate wyeth 2,5MG
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-SE   Czech Republic;Sweden
Methylprednisolone
   Department of Neurology and Rheumatology, Shinshu University School of Medicine
      2009   -   JPRN-UMIN000001866   Japan
   Department of rheumatology, China-Japan Friendship hospital
      2013   -   ChiCTR-TRC-13003178   China
   Hamamatsu University School of Medicine
      2018   -   JPRN-UMIN000032022   Japan
   ISTITUTO GIANNINA GASLINI
      2006   -   EUCTR2005-003956-37-IT   Belgium;Italy;Netherlands;Sweden;United Kingdom
   Istituto Giannina Gaslini
      2008   -   EUCTR2005-003956-37-GB   Belgium;Italy;Netherlands;Sweden;United Kingdom
      2007   -   EUCTR2005-003956-37-SE   Belgium;Italy;Netherlands;Sweden;United Kingdom
      2006   -   EUCTR2005-003956-37-NL   Belgium;Italy;Netherlands;Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-003956-37-DK   Belgium;Denmark;Italy;Netherlands;Sweden;United Kingdom
   Northwestern University
      1997   Phase 2   NCT00004357   United States
   Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
      2018   -   JPRN-UMIN000032193   Japan
   Second Division, Department of Internal medicine, Hamamatsu University School of Medicine
      2014   -   JPRN-UMIN000015469   Japan
Methylprednisolone sodium succinate
   University Hospital Gent
      2006   Phase 3   EUCTR2005-003956-37-BE   Belgium;Denmark;Italy;Netherlands;Sweden;United Kingdom
Methylprednisoloni natrii succinas
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-CZ   Czech Republic;Sweden
Metoject 10 MG/ML
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-SE   Czech Republic;Sweden
Metotrexat
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-SE   Czech Republic;Sweden
Metotrexate
   Istituto Giannina Gaslini
      2006   Phase 3   EUCTR2005-003956-37-DK   Belgium;Denmark;Italy;Netherlands;Sweden;United Kingdom
MMF
   Department of rheumatology, China-Japan Friendship hospital
      2013   -   ChiCTR-TRC-13003178   China
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
MMF discontinuation
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
MMF maintain
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
Moderna MRNA-1273, bivalent
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
Monovalent [B.1.351] COV2 pres DTM-AS03
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
MPA
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
MSC-exos nebulization therapy
   Li Shiyue
      2025   Phase 1   NCT06919380   China
MTX
   Department of rheumatology, China-Japan Friendship hospital
      2013   -   ChiCTR-TRC-13003178   China
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States
MTX discontinuation
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
MTX maintain
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
Neisseria meningitidis group A polysaccharide conjugated with tetanus toxoid carrier protein
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-IT   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States
Neisseria meningitidis group W-135 polysaccharide conjugated TO teta
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-IT   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States
Neisseria meningitidis group W-135 polysaccharide conjugated TO tetanus toxoid carrier protein
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-IT   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States
Nimenrix
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-IT   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States
Nivolumab
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States
NM8074
   NovelMed Therapeutics
      2026   Phase 2   NCT06887738   -
Octanorm
   Octapharma
      2018   Phase 3   NCT03686969   Czechia;Germany;Hungary;Poland;Romania;Russian Federation
   Octapharma Pharmazeutika Produktionsges.m.b.H
      2018   Phase 3   EUCTR2017-002710-31-RO   Canada;Czech Republic;Germany;Hungary;Romania;Russian Federation;United States
      2018   Phase 3   EUCTR2017-002710-31-HU   Canada;Czech Republic;Germany;Hungary;Russian Federation;United States
      2018   Phase 3   EUCTR2017-002710-31-DE   Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;United States
      2018   Phase 3   EUCTR2017-002710-31-CZ   Canada;Czech Republic;Germany;Hungary;Russian Federation;United States
Olumiant 4MG
   Assistance Publique-Hopitaux de Paris
      2021   Phase 3   EUCTR2020-004987-24-FR   France
Olumiant® 2 MG compriméS PélliculéS
   Assistance Publique des Hôpitaux de Paris
      2022   Phase 2   EUCTR2022-000506-10-FR   France
ONE alpha drops
   Belfast Health and Social Care Trust, Musgrave Park Hospital
      2006   Phase 4   EUCTR2005-003129-23-GB   United Kingdom
ONE-alpha drops
   Belfast Health and Social Care Trust, Musgrave Park Hospital
      2006   Phase 4   EUCTR2005-003129-23-GB   United Kingdom
Orencia
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2018   Phase 3   EUCTR2016-002269-77-IT   Australia;Brazil;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Mexico;Sweden;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-002269-77-SE   Australia;Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Sweden;United States
      2017   Phase 3   EUCTR2016-002269-77-FR   Australia;Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Sweden;United States
      2017   Phase 3   EUCTR2016-002269-77-DE   Australia;Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Sweden;United States
      2017   Phase 3   EUCTR2016-002269-77-CZ   Australia;Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Sweden;United States
   Karolinska University Hospital
      2012   -   EUCTR2009-015957-20-GB   Sweden;United Kingdom
      2011   Phase 2   EUCTR2009-015957-20-CZ   Czech Republic;Sweden;United Kingdom
      2010   -   EUCTR2009-015957-20-SE   Sweden;United Kingdom
PBO
   argenx
      2022   Phase 2/Phase 3   NCT05523167   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Cyprus;Czechia;Denmark;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States
PF-06823859
   Kawai Norisuke
      2023   Phase 3   JPRN-jRCT2031230382   Japan;United States
   PFIZER INC
      2021   Phase 2   EUCTR2020-004228-41-IT   Germany;Hungary;Italy;Poland;Spain;United States
   Pfizer
      2023   Phase 3   NCT05895786   Argentina;Belgium;Bulgaria;China;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Poland;Slovakia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 2   NCT05192200   Hungary;Poland;Spain;United States
   Pfizer Inc.
      2022   Phase 2   EUCTR2021-004787-10-PL   Australia;Germany;Hungary;Italy;Poland;Spain;United States
      2022   Phase 2   EUCTR2021-004787-10-HU   Australia;Germany;Hungary;Italy;Poland;Spain;United States
      2022   Phase 2   EUCTR2021-004787-10-ES   Australia;Germany;Hungary;Italy;Poland;Spain;United States
      2022   Phase 2   EUCTR2021-004787-10-DE   Australia;Germany;Hungary;Italy;Poland;Spain;United States
      2021   Phase 2   EUCTR2020-004228-41-PL   Germany;Hungary;Italy;Poland;Spain;United States
      2021   Phase 2   EUCTR2020-004228-41-HU   Germany;Hungary;Italy;Poland;Spain;United States
      2021   Phase 2   EUCTR2020-004228-41-ES   Germany;Hungary;Italy;Poland;Spain;United States
      2021   Phase 2   EUCTR2020-004228-41-DE   Germany;Hungary;Italy;Poland;Spain;United States
PF-06823859 high
   Pfizer
      2018   Phase 2   NCT03181893   Australia;Germany;Hungary;Italy;Poland;Spain;United States
PF-06823859 LOW
   Pfizer
      2018   Phase 2   NCT03181893   Australia;Germany;Hungary;Italy;Poland;Spain;United States
Pharmacokinetics study
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT05524311   France
Pirfenidone
   Beijing Continent Pharmaceutical Co, Ltd.
      2018   Phase 3   NCT03857854   China
   RenJi Hospital
      2016   Phase 4   NCT02821689   China
   Renji Hospital, Shanghai Jiaotong University School of Medicine
      2014   -   ChiCTR-IPR-16007958   China
PN-101
   Paean Biotechnology Inc.
      2021   Phase 1/Phase 2   NCT04976140   Korea, Republic of
Pneumovax 23
   Radboud University Nijmegen Medical Centre
      2008   -   EUCTR2008-001282-28-NL   Netherlands
Polyethylene glycol
   Japan Blood Products Organization
      2006   Phase 3   JPRN-jRCT2080220256   Japan
Prednisolon pfizer
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-SE   Czech Republic;Sweden
Prednisolone
   Department of Neurology and Rheumatology, Shinshu University School of Medicine
      2009   -   JPRN-UMIN000001866   Japan
   Department of rheumatology, China-Japan Friendship hospital
      2013   -   ChiCTR-TRC-13003178   China
   Furuta Shunsuke
      2024   Phase 2   JPRN-jRCT2031240191   -
   Hamamatsu University School of Medicine
      2018   -   JPRN-UMIN000032022   Japan
   Northwestern University
      1997   Phase 2   NCT00004357   United States
   Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
      2018   -   JPRN-UMIN000032193   Japan
   Second Division, Department of Internal medicine, Hamamatsu University School of Medicine
      2014   -   JPRN-UMIN000015469   Japan
   University Hospital Gent
      2006   Phase 3   EUCTR2005-003956-37-BE   Belgium;Denmark;Italy;Netherlands;Sweden;United Kingdom
Prednison 5, 20 Léciva POR. tablet NOB
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-CZ   Czech Republic;Sweden
Prednisone
   Children's Hospital Medical Center, Cincinnati
      2002   Phase 2/Phase 3   NCT00035958   United States
   Department of rheumatology, China-Japan Friendship hospital
      2013   -   ChiCTR-TRC-13003178   China
   ISTITUTO GIANNINA GASLINI
      2006   -   EUCTR2005-003956-37-IT   Belgium;Italy;Netherlands;Sweden;United Kingdom
   Institute of Rheumatology, Prague
      2008   Phase 3   NCT00651040   Czech Republic
   Istituto Giannina Gaslini
      2008   -   EUCTR2005-003956-37-GB   Belgium;Italy;Netherlands;Sweden;United Kingdom
      2007   -   EUCTR2005-003956-37-SE   Belgium;Italy;Netherlands;Sweden;United Kingdom
      2006   -   EUCTR2005-003956-37-NL   Belgium;Italy;Netherlands;Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-003956-37-DK   Belgium;Denmark;Italy;Netherlands;Sweden;United Kingdom
Pregnancy test
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT05524311   France
Ravulizumab
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-IT   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States
   Alexion Pharmaceuticals, Inc.
      2021   Phase 2/Phase 3   NCT04999020   France;Germany;Italy;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-FR   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-ES   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Peru;Poland;Serbia;Spain;Sweden;Taiwan;Türkiye;United Kingdom;United States
   Kobayashi Hiroshi
      2022   Phase 2-3   JPRN-jRCT2031210681   France;Germany;Italy;Japan;UK;USA
RAY121
   Chugai Pharmaceutical
      2024   Phase 1   NCT06723106   Australia;Austria;Bulgaria;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Romania;Spain;Taiwan;Turkey
      2024   Phase 1   NCT06371417   Australia;Austria;Bulgaria;Canada;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United States
Resunab, ajulemic acid, anabasum
   Corbus Pharmaceuticals, Inc.
      2020   Phase 2;Phase 3   EUCTR2020-001762-11-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2020   Phase 2;Phase 3   EUCTR2020-001762-11-GB   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-SE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-HU   Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Serbia;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-GB   Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Serbia;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-ES   Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Serbia;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-DE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-CZ   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003273-10-BG   Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2020-001762-11-SE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2020-001762-11-DE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2020-001762-11-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
Risedronate sodium
   Belfast Health and Social Care Trust, Musgrave Park Hospital
      2006   Phase 4   EUCTR2005-003129-23-GB   United Kingdom
Rituximab
   Karolinska University Hospital
      2007   -   EUCTR2006-000078-65-SE   Czech Republic;Sweden;United Kingdom
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom
   University of Pittsburgh
      2006   Phase 2   NCT00106184   Canada;Czech Republic;Sweden;United Kingdom;United States
   Yokohama City University Hospital Department of Pediatrics
      2015   -   JPRN-UMIN000018376   Japan
Roactemra 162 MG soluzione iniettabile IN siringa preriempita
   Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia
      2018   Phase 2   EUCTR2018-000391-15-IT   Italy
Ruxolitinib topical cream
   The Cleveland Clinic
      2025   Phase 2   NCT06857240   -
S78989
   Institut de Recherches Internationales Servier (IRIS)
      2014   -   EUCTR2012-005772-34-GR   Australia;Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Poland;South Africa;Spain;Sweden;United Kingdom
      2014   -   EUCTR2012-005772-34-BE   Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Poland;South Africa;Spain;Sweden;United Kingdom
      2013   -   EUCTR2012-005772-34-SE   Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Poland;South Africa;Spain;Sweden;United Kingdom
      2013   Phase 2   EUCTR2012-005772-34-IT   Argentina;Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
      2013   -   EUCTR2012-005772-34-HU   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;Sweden;United Kingdom
      2013   -   EUCTR2012-005772-34-DE   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;Sweden;United Kingdom
      2013   Phase 2   EUCTR2012-005772-34-CZ   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
   Laboratorios Servier S.L
      2013   -   EUCTR2012-005772-34-ES   Argentina;Belgium;Brazil;Czech Republic;Denmark;France;Germany;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
   Servier Research and Development Ltd.
      2014   Phase 2   EUCTR2012-005772-34-GB   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
Siponimid
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2012-002859-42-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Taiwan;United States
      2013   Phase 2   EUCTR2012-002859-42-HU   Belgium;Canada;Czech Republic;Hungary;Poland;United States
      2013   Phase 2   EUCTR2012-002859-42-CZ   Belgium;Canada;Czech Republic;Hungary;Poland;United States
Siponimod
   Novartis Pharma Services AG
      2014   -   EUCTR2013-001799-39-PL   Canada;Czech Republic;Germany;Hungary;Japan;Poland;United States
      2014   Phase 2   EUCTR2013-001799-39-BE   Belgium;Canada;Czech Republic;Germany;Hungary;Japan;Poland;Taiwan;United States
      2014   Phase 2   EUCTR2012-002859-42-BE   Belgium;Canada;Czech Republic;Hungary;Poland;Taiwan;United States
      2013   -   EUCTR2013-001799-39-HU   Belgium;Canada;China;Czech Republic;Germany;Hungary;Japan;Netherlands;Poland;Switzerland;Taiwan;United States
      2013   -   EUCTR2013-001799-39-CZ   Canada;Czech Republic;Germany;Hungary;Japan;Poland;United States
      2013   Phase 2   EUCTR2012-002859-42-HU   Belgium;Canada;Czech Republic;Hungary;Poland;United States
      2013   Phase 2   EUCTR2012-002859-42-CZ   Belgium;Canada;Czech Republic;Hungary;Poland;United States
Siponimod 0.25 MG tablet
   Novartis Pharma Services AG
      2013   Phase 2   EUCTR2012-002859-42-PL   Belgium;Canada;Czech Republic;Hungary;Poland;Switzerland;Taiwan;United States
Siponimod 0.5 MG tablet
   Novartis Pharma Services AG
      2013   Phase 2   EUCTR2012-002859-42-PL   Belgium;Canada;Czech Republic;Hungary;Poland;Switzerland;Taiwan;United States
Siponimod 1 MG tablet
   Novartis Pharma Services AG
      2013   Phase 2   EUCTR2012-002859-42-PL   Belgium;Canada;Czech Republic;Hungary;Poland;Switzerland;Taiwan;United States
Siponimod 2 MG tablet
   Novartis Pharma Services AG
      2013   Phase 2   EUCTR2012-002859-42-PL   Belgium;Canada;Czech Republic;Hungary;Poland;Switzerland;Taiwan;United States
Sodium thiosulfate
   Alison Ehrlich
      2012   Phase 2   NCT01572844   United States
   National Institute of Environmental Health Sciences (NIEHS)
      2017   Phase 2/Phase 3   NCT03267277   United States
   Robyn T. Domsic, MD, MPH
      2025   Phase 2   NCT06672822   United States
Sodium thiosulfate pentahydrate
   CHU de LIMOGES
      2019   Phase 2   EUCTR2018-001978-22-FR   France
SOLU-medrol INJ. PSO LQF 40MG
   Institute od Rheumatology Prague
      2008   -   EUCTR2007-004410-13-CZ   Czech Republic;Sweden
Steroids
   RenJi Hospital
      2017   Phase 2   NCT03192657   China
STS
   Robyn T. Domsic, MD, MPH
      2025   Phase 2   NCT06672822   United States
   University Hospital, Limoges
      2020   Phase 2   NCT03582800   France
Tacrolimus
   Astellas Pharma Inc
      2014   -   NCT02159651   Japan
   Department of Rheumatology and Immunology, Tianjin Medical University General Hospital
      2020   Phase 4   ChiCTR1900028143   China
   Furuta Shunsuke
      2024   Phase 2   JPRN-jRCT2031240191   -
   Hamamatsu University School of Medicine
      2018   -   JPRN-UMIN000032022   Japan
   IMPPACT study central office
      2007   Phase 2-3   JPRN-jRCT1091220012   Japan
   Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
      2018   -   JPRN-UMIN000032193   Japan
   Second Division, Department of Internal medicine, Hamamatsu University School of Medicine
      2014   -   JPRN-UMIN000015469   Japan
   Tokyo Medical and Dental University
      2007   Phase 2/Phase 3   NCT00504348   Japan
Tetanus protein
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-IT   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States
Tocilizumab
   Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia
      2018   Phase 2   EUCTR2018-000391-15-IT   Italy
   Chester Oddis
      2014   Phase 2   NCT02043548   United States
Tofacitinib
   Johns Hopkins University
      2017   Phase 1   NCT03002649   United States
   Ren Ji Hospital South Campus, Shanghai Jiaotong University School of Medicine
      2017   -   ChiCTR1800016629   China
   Zhongshan Hospital of Fudan University
      2020   -   ChiCTR2000036709   China
Tofacitinib 5 MG
   Furuta Shunsuke
      2024   Phase 2   JPRN-jRCT2031240191   -
   Jing Liang
      2020   -   NCT04613219   China
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2024   Phase 4   NCT06438679   China
Transcriptomic analysis
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT05524311   France
Treatment defined only BY active substance
   Istituto Giannina Gaslini
      2008   -   EUCTR2005-003956-37-GB   Belgium;Italy;Netherlands;Sweden;United Kingdom
      2007   -   EUCTR2005-003956-37-SE   Belgium;Italy;Netherlands;Sweden;United Kingdom
Triple therapy
   Furuta Shunsuke
      2024   Phase 2   JPRN-jRCT2031240191   -
   The First Affiliated Hospital with Nanjing Medical University
      2022   Phase 4   NCT05375435   China
Ultomiris
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-IT   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States
   Alexion Pharmaceuticals, Inc.
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-FR   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-ES   France;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2021-001200-15-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Peru;Poland;Serbia;Spain;Sweden;Taiwan;Türkiye;United Kingdom;United States
Umbilical cord lining stem cells
   University of Florida
      2021   Early Phase 1   NCT04723303   United States
Ustekinumab
   Janssen Pharmaceutical K.K.
      2019   Phase 3   JPRN-jRCT2080224745   Japan
Ustekinumab 6 MG/KG
   Janssen Pharmaceutical K.K.
      2019   Phase 3   NCT03981744   Japan
Ustekinumab 90 MG
   Janssen Pharmaceutical K.K.
      2019   Phase 3   NCT03981744   Japan
VIB7734
   Amgen
      2018   Phase 1   NCT03817424   Poland;Spain;United States
Vitamin D
   UMC Utrecht
      2000   Phase 3   NCT00138983   Netherlands
Xoma 052
   Institut de Recherches Internationales Servier (IRIS)
      2014   -   EUCTR2012-005772-34-GR   Australia;Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Poland;South Africa;Spain;Sweden;United Kingdom
      2014   -   EUCTR2012-005772-34-BE   Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Poland;South Africa;Spain;Sweden;United Kingdom
      2013   -   EUCTR2012-005772-34-SE   Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Poland;South Africa;Spain;Sweden;United Kingdom
      2013   Phase 2   EUCTR2012-005772-34-IT   Argentina;Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
      2013   -   EUCTR2012-005772-34-HU   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;Sweden;United Kingdom
      2013   -   EUCTR2012-005772-34-DE   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;Sweden;United Kingdom
      2013   Phase 2   EUCTR2012-005772-34-CZ   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
   Laboratorios Servier S.L
      2013   -   EUCTR2012-005772-34-ES   Argentina;Belgium;Brazil;Czech Republic;Denmark;France;Germany;Hungary;Italy;Norway;Spain;Sweden;United Kingdom
   Servier Research and Development Ltd.
      2014   Phase 2   EUCTR2012-005772-34-GB   Belgium;Brazil;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom
Yellow fever vaccine
   University of Sao Paulo General Hospital
      2018   -   NCT03430388   Brazil